Study Title

A Phase II Single Arm Trial Evaluating the Preliminary Efficacy of the Combination of 177Lu-DOTATATE and Nivolumab in Grade 3 Well-differentiated Neuroendocrine Tumours (NET) or Poorly Differentiated Neuroendocrine Carcinomas (NEC)

Study Details

Description:

This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine tumours (NET) or neuroendocrine carcinomas (NEC)

Sponsor:

Fundación de investigación HM

Contacts:

Antonio Cubillo, MD

secretaria@fundacionhm.com

+34 917567800

Government Study Link:

NCT04525638 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468